Skip to main content

Table 1 Baseline characteristics for the 97 patients included in the safety analysis. Data are presented as mean ± SD (range). In case of missing data, the number of evaluated patients is given in parentheses

From: Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry

Baseline characteristics (n = 97 evaluated for safety)
Age 46.6 ± 11.7 (22–75)
Gender 71 Male/26 Female
Cluster headache subtype 88 Chronic/9 Episodic
Laterality of headache 56 Left/41 Right
Cluster headache duration (years) 13.4 ± 9.0 (1–44) (n = 95)
Cluster attack frequency (per week) 25.6 ± 20.9 (0–96) (n = 95)
HIT-6 score at baseline 64.4 ± 6.4 (41–78) (n = 92)
Preventive medications at baseline 28% (27/97) used no preventive medications
72% (70/97) used preventive medications
Of these: 48% (47/97) used verapamil as monotherapy or part of polytherapy, 24% (23/97) used other medicationsa
  1. HIT-6 Headache Impact Test
  2. aTopiramate, valproic acid, gabapentin, lithium carbonate, melatonin, methysergide, ergotamine and indomethacin